SG11202100385YA - Use of riluzole prodrugs to treat alzheimer's disease - Google Patents
Use of riluzole prodrugs to treat alzheimer's diseaseInfo
- Publication number
- SG11202100385YA SG11202100385YA SG11202100385YA SG11202100385YA SG11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- treat alzheimer
- riluzole prodrugs
- riluzole
- prodrugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701814P | 2018-07-22 | 2018-07-22 | |
| PCT/US2019/042718 WO2020023324A1 (en) | 2018-07-22 | 2019-07-20 | Use of riluzole prodrugs to treat alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100385YA true SG11202100385YA (en) | 2021-02-25 |
Family
ID=69181140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100385YA SG11202100385YA (en) | 2018-07-22 | 2019-07-20 | Use of riluzole prodrugs to treat alzheimer's disease |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12161633B2 (https=) |
| EP (1) | EP3823616A4 (https=) |
| JP (2) | JP2021530543A (https=) |
| KR (1) | KR20210034621A (https=) |
| CN (1) | CN112469408A (https=) |
| AU (1) | AU2019310013B2 (https=) |
| BR (1) | BR112021000768A2 (https=) |
| CA (1) | CA3107215A1 (https=) |
| EA (1) | EA202190308A1 (https=) |
| IL (1) | IL280177B2 (https=) |
| MX (2) | MX2021000515A (https=) |
| NZ (1) | NZ772009A (https=) |
| PH (1) | PH12021550043A1 (https=) |
| SG (1) | SG11202100385YA (https=) |
| WO (1) | WO2020023324A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7805969B2 (ja) * | 2020-06-24 | 2026-01-26 | バイオヘイブン・セラピューティクス・リミテッド | 強迫性障害を治療するための組成物及び方法 |
| US20240016783A1 (en) * | 2020-10-05 | 2024-01-18 | Icahn School Of Medicine At Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
| AU2022222778A1 (en) * | 2021-02-22 | 2023-08-31 | Yale University | Targeted bifunctional degraders and methods using same |
| CN114344297B (zh) * | 2022-03-01 | 2024-05-14 | 暨南大学 | 利鲁唑在治疗少精症中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501875A (ja) * | 2000-06-14 | 2004-01-22 | メダレックス，インコーポレイティド | トリペプチドプロドラッグ化合物 |
| JP2008518935A (ja) * | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| CA2933464A1 (en) | 2013-12-09 | 2015-06-18 | Thomas Jefferson University | Use of abc drug efflux inhibitors in combination with anti-neurodegenerative drugs in the treatment of neurodegenerative disorders |
| KR102462638B1 (ko) * | 2014-11-26 | 2022-11-03 | 메디시노바, 인크. | 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법 |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| LT3458053T (lt) * | 2016-05-20 | 2022-02-25 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui |
| WO2018031707A1 (en) | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| TW202000205A (zh) * | 2018-02-21 | 2020-01-01 | 美商Ａｉ治療公司 | 使用阿吡莫德與麩胺酸性劑的組合治療 |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
-
2019
- 2019-07-20 MX MX2021000515A patent/MX2021000515A/es unknown
- 2019-07-20 EP EP19841953.3A patent/EP3823616A4/en active Pending
- 2019-07-20 EA EA202190308A patent/EA202190308A1/ru unknown
- 2019-07-20 CN CN201980048687.7A patent/CN112469408A/zh active Pending
- 2019-07-20 WO PCT/US2019/042718 patent/WO2020023324A1/en not_active Ceased
- 2019-07-20 IL IL280177A patent/IL280177B2/en unknown
- 2019-07-20 CA CA3107215A patent/CA3107215A1/en active Pending
- 2019-07-20 NZ NZ772009A patent/NZ772009A/en unknown
- 2019-07-20 SG SG11202100385YA patent/SG11202100385YA/en unknown
- 2019-07-20 US US17/261,057 patent/US12161633B2/en active Active
- 2019-07-20 KR KR1020217004639A patent/KR20210034621A/ko not_active Ceased
- 2019-07-20 AU AU2019310013A patent/AU2019310013B2/en active Active
- 2019-07-20 JP JP2021503571A patent/JP2021530543A/ja active Pending
- 2019-07-20 BR BR112021000768-7A patent/BR112021000768A2/pt unknown
-
2021
- 2021-01-07 PH PH12021550043A patent/PH12021550043A1/en unknown
- 2021-01-14 MX MX2024010655A patent/MX2024010655A/es unknown
-
2025
- 2025-02-21 JP JP2025026643A patent/JP2025093952A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3823616A1 (en) | 2021-05-26 |
| IL280177B1 (en) | 2024-09-01 |
| JP2021530543A (ja) | 2021-11-11 |
| US20210290599A1 (en) | 2021-09-23 |
| MX2024010655A (es) | 2024-09-11 |
| NZ772009A (en) | 2026-02-27 |
| AU2019310013B2 (en) | 2025-01-02 |
| BR112021000768A2 (pt) | 2021-05-11 |
| PH12021550043A1 (en) | 2021-09-20 |
| EP3823616A4 (en) | 2022-05-04 |
| WO2020023324A1 (en) | 2020-01-30 |
| IL280177A (en) | 2021-03-01 |
| KR20210034621A (ko) | 2021-03-30 |
| US12161633B2 (en) | 2024-12-10 |
| MX2021000515A (es) | 2021-06-08 |
| AU2019310013A1 (en) | 2021-02-11 |
| IL280177B2 (en) | 2025-01-01 |
| CN112469408A (zh) | 2021-03-09 |
| JP2025093952A (ja) | 2025-06-24 |
| CA3107215A1 (en) | 2020-01-30 |
| EA202190308A1 (ru) | 2021-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280177A (en) | Use of riluzole prodrugs to treat Alzheimer's disease | |
| IL276493A (en) | Carbidopa and L-dopa prodrugs and methods for use in the treatment of Parkinson's disease | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| IL265528A (en) | aav therapy for Huntington's disease | |
| IL274648A (en) | Promote new catecholamine drugs for use in the treatment of Parkinson's disease | |
| IL254030B (en) | Use of pyridofidine to improve cognitive function and to treat Alzheimer's disease | |
| EP3562514A4 (en) | GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE | |
| IL275321A (en) | Treatment of diseases associated with the expression of DUX4 | |
| IL274532A (en) | Using the prodrug riluzole to treat ataxias | |
| SI3720433T1 (sl) | Bis-holin tetratiomolibdat za zdravljenje Wilsonove bolezni | |
| HUE059387T2 (hu) | Parkinson-kór kezelése | |
| SG11202011187QA (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| IL280657A (en) | Use of riluzole oral dissolving tablets to treat diseases | |
| EP3373888A4 (en) | METHOD FOR THE TREATMENT OF SKIN DISEASES USING PLASMONIC NANOPARTICLES | |
| EP4277624A4 (en) | USE OF RILUZOLE PRODRUGS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| IL290726A (en) | Use of Brazicomb to treat Crohn's disease | |
| HK40041745A (en) | Use of riluzole prodrugs to treat alzheimer's disease | |
| ZA202001588B (en) | Method of treating alzheimer's disease | |
| HK40068889A (en) | Use of brazikumab to treat crohn's disease | |
| HK40037165A (en) | New catecholamine prodrugs for use in the treatment of parkinson's disease | |
| AU2017902307A0 (en) | Treatment of alzheimer's disease | |
| AU2017902309A0 (en) | Treatment of alzheimer's disease | |
| GB201504144D0 (en) | Treatment of Parkinson's disease |